Scarica l'app Stockscreener
26.40
5.07%
-1.41
Dopo l'orario di chiusura:
26.85
0.45
+1.70%
Precedente Chiudi:
$27.81
Aprire:
$27.56
Volume 24 ore:
333.32K
Relative Volume:
0.63
Capitalizzazione di mercato:
$1.28B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-12.90%
1M Prestazione:
-16.04%
6M Prestazione:
+97.16%
1 anno Prestazione:
+38.87%
Intervallo 1D:
$25.79
$27.76
Intervallo di 1 settimana:
$25.23
$30.61
Portata 52W:
$5.485
$32.64
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Nome
Oruka Therapeutics Inc
Settore
Industria
Telefono
650-606-7910
Indirizzo
855 OAK GROVE AVE., MENLO PARK
Confronta ORKA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
26.40 | 1.35B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-18 | Iniziato | Piper Sandler | Overweight |
| 2025-11-13 | Iniziato | Jefferies | Buy |
| 2025-10-27 | Iniziato | Guggenheim | Buy |
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-05-22 | Iniziato | BTIG Research | Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-10-11 | Iniziato | Stifel | Buy |
| 2024-10-07 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-17 | Iniziato | Leerink Partners | Outperform |
| 2024-09-16 | Iniziato | TD Cowen | Buy |
| 2024-09-13 | Iniziato | Jefferies | Buy |
| 2018-02-27 | Iniziato | Ascendiant Capital Markets | Buy |
| 2013-10-09 | Iniziato | Dawson James | Buy |
Mostra tutto
Oruka Therapeutics Inc Borsa (ORKA) Ultime notizie
Why Oruka Therapeutics Inc. stock is a must watch in 2025Earnings Beat & AI Powered Market Entry Strategies - ulpravda.ru
How buybacks impact Oruka Therapeutics Inc. stock value2025 Momentum Check & Short-Term Swing Trade Alerts - ulpravda.ru
Is Oruka Therapeutics Inc. (HQ1) stock undervalued historicallyJuly 2025 Technicals & Reliable Price Breakout Alerts - ulpravda.ru
Can Oruka Therapeutics Inc. stock attract ESG capital inflowsJuly 2025 Trade Ideas & Reliable Breakout Stock Forecasts - ulpravda.ru
Aug Outlook: Why Oruka Therapeutics Inc. stock is favored by top institutions2025 Retail Activity & Real-Time Volume Spike Alerts - ulpravda.ru
What sentiment indicators say about Oruka Therapeutics Inc. stockJuly 2025 Institutional & Technical Buy Zone Confirmations - ulpravda.ru
Is Oruka Therapeutics Inc. stock a dividend growth opportunity - ulpravda.ru
Oruka Therapeutics stock initiated with Buy rating at UBS on cancer drug potential - Investing.com Canada
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Oruka Therapeutics: ORKA-001 For Psoriasis In Focus As 2026 Phase 2 Data Nears - Seeking Alpha
ORKA-001 psoriasis trial: Fresh phase 2 update and what it means for investors - MSN
Oruka Therapeutics (NASDAQ:ORKA) Trading Down 8.3%What's Next? - MarketBeat
Oruka Therapeutics Builds Oncology Programs at Molecular Level - Kalkine Media
Insider Sell Alert: Laura Sandler Sells 13,000 Shares of Oruka T - GuruFocus
Oruka Therapeutics COO Sandler sells $370,795 in shares By Investing.com - Investing.com Canada
Oruka Therapeutics COO Sandler sells $370,795 in shares - Investing.com UK
Oruka Therapeutics (NASDAQ:ORKA) Stock Price Up 4.3% – Time to Buy? - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Shares Up 4.3%Should You Buy? - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Trading Down 3.3%Time to Sell? - MarketBeat
Wolfe Research Initiates Coverage of Oruka Therapeutics (ORKA) with Outperform Recommendation - MSN
Rigel Pharmaceuticals (NASDAQ:RIGL) and Oruka Therapeutics (NASDAQ:ORKA) Financial Survey - Defense World
Oruka Therapeutics inks exclusive license deal with Paragon - MSN
Oruka Therapeutics (ORKA): Valuation Check After Board Appointment of Commercial Veteran Chris Martin - Sahm
Oruka Therapeutics (NASDAQ:ORKA) Reaches New 12-Month HighHere's What Happened - MarketBeat
Oruka Therapeutics stock hits 52-week high at 32.31 USD By Investing.com - Investing.com Australia
Oruka Therapeutics stock hits 52-week high at 32.31 USD - Investing.com India
Financial Enhancement Group LLC Takes Position in Oruka Therapeutics, Inc. $ORKA - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Insider Sells $214,270.00 in Stock - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Shares Up 11.3%Here's What Happened - MarketBeat
Piper Sandler Begins Coverage on Oruka Therapeutics (NASDAQ:ORKA) - MarketBeat
How Oruka Therapeutics Inc. stock compares to growth peersWeekly Gains Report & AI Based Buy and Sell Signals - Улправда
ORKA-001 Psoriasis Trial: Fresh Phase 2 Update and What It Means for Investors - TipRanks
Oruka Therapeutics Earnings Notes - Trefis
Braidwell LP Cuts Stake in Oruka Therapeutics, Inc. $ORKA - MarketBeat
Oruka Therapeutics appoints Chris Martin to board of directors By Investing.com - Investing.com India
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Oruka Therapeutics appoints Chris Martin to board of directors - Investing.com
Oruka Therapeutics Appoints Christopher Martin to Board - TipRanks
Oruka Therapeutics Announces New Board Member and Board Transition - The Manila Times
B Group Inc. Increases Position in Oruka Therapeutics, Inc. $ORKA - Defense World
Oruka Therapeutics (ORKA) Stock Analysis Report | Financials & Insights - Benzinga
Oruka Therapeutics, Inc. $ORKA Shares Purchased by Geode Capital Management LLC - Defense World
Oruka Therapeutics, Inc. $ORKA Shares Purchased by Affinity Asset Advisors LLC - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Sets New 52-Week HighWhat's Next? - MarketBeat
Oruka Therapeutics stock hits 52-week high, reaching $31.01 By Investing.com - Investing.com Nigeria
Can Oruka Therapeutics Inc. stock deliver consistent earnings growthCEO Change & AI Based Buy and Sell Signals - Newser
Will Oruka Therapeutics Inc. stock sustain high P E ratios2025 Volatility Report & Safe Capital Growth Plans - Newser
Is Oruka Therapeutics Inc. (HQ1) stock dividend growth reliable2025 Risk Factors & Consistent Profit Trading Strategies - Newser
Oruka Therapeutics stock hits 52-week high, reaching $31.01 - Investing.com
Oruka Therapeutics Inc Azioni (ORKA) Dati Finanziari
Non sono disponibili dati finanziari per Oruka Therapeutics Inc (ORKA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):